P53 overexpression impacts on the prognosis of laryngeal squamous cell carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1731-1734

  Jalali, Mir Mohammad ^a   Heidarzadeh, Abtin ^b   Zavarei, Mansour Jamali ^c   Sarmast, Hadi ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Laryngeal SCC; P53 gene expression; Prognosis; Recurrence; Tumour margins

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; DISEASE FREE SURVIVAL; HUMAN; LARYNX TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SMOKING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864348912     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Almadori G, Bussu F, Cadoni G, et al (2005). Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer, 41, 683-93.
2. Armstrong WB, Vokes DE, Maisel RH (2010). Malignant tumors of the larynx. In: Flint Pw, Haughey BH, Lund VJ, et al, eds. Cummings otolaryngology head & neck surgery. 5th ed. Mosby Elsevier, 1482-511.
3. Blons H, Laurent-Puig P (2003). TP53 and head and neck neoplasms. Hum Mutat, 21, 252-7.
4. Bosch FX, Ritter D, Enders C, et al (2004). Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer, 111, 530-8.
5. Brennan JA, Mao L, Hruban RH, et al (1995). Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med, 332, 429-35.
6. Cabanillas R, Rodrigo JP, Astudillo A, et al (2007). P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question. Cancer, 109, 1791-8.
7. Ferlito, A, Shaha AR, Rinaldo A (2002). The incidence of lymph node micrometastases in patients pathologically staged N0 in cancer of oral cavity and oropharynx. Oral Oncol, 38, 3-5.
8. Freier K, Joos S, Flechtenmacher C, et al (2005). Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Head Neck, 27, 710-7.
9. Hardisson D (2003). Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol, 260, 502-8.
10. Homann N, Nees M, Conradt C, et al (2001). Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res, 7, 290-6.
11. Rodrigo JP, Suárez C, González MV, et al (2001). Variability of genetic alterations in different sites of head and neck cancer. Laryngoscope, 111, 1297-301.
12. Rodrigues RB, Motta Rda R, Machado SM, et al (2008). Prognostic value of the immunohistochemistry correlation of Ki-67 and p53 in squamous cell carcinomas of the larynx. Braz J Otorhinolaryngol, 74, 855-9.
13. Roepman P, Wessels LF, Kettelarij N, et al (2005). An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet, 37, 182-186.
14. Vlachtsis K, Nikolaou A, Markou K, et al (2005). Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol, 262, 890-8.
15. Waitzberg AF, Nonogaki S, Nishimoto IN, et al (2004). Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev, 28, 178-86.